InvestorsHub Logo

plexrec

12/21/22 4:01 PM

#393927 RE: Mikesc #393923

Mikesc--" I believe the stock is worth over $180 per share based on the $14 billion estimate,"--many thanks for posting this summary !!!! Our stock much undervalued !!!!!

gbrown6332

12/21/22 4:13 PM

#393933 RE: Mikesc #393923

Highly gratifying to read an upbeat assessment of December 1st results.

Really looking forward to the January 12 session at the J.P. Morgan conference.

bas2020

12/22/22 12:50 AM

#393989 RE: Mikesc #393923

Excellent and honest review! I particularly like this quote...

The latest trial was a Phase 2b/3 trial and may lead to FDA approval of Blarcamesine.


Though it seems some didn't "like" the review as it goes against the false narrative.